25CN-NBOH is a brain-penetrant, highly potent and selective 5-HT2A receptor agonist (human 2A/rat 2C Ki = 1.3/132 nM; human 2A/2C PI turnover EC50 = 2.1/190 nM) with much reduced efficacy toward human 2B & 2C subtypes (Ki ratio: 2C/2A = 52-81 & 2B/2A = 37; Ca2+ mobilization Δlog(Rmax/EC50 ratio: 2C/2A = 30-180 & 2B/2A = 54; 2C/2A PI turnover EC50 ratio = 81-146) and other receptors/transporters/kinases. When administered in mice in vivo (1, 3, 6 mg/kg s.c.), 25CN-NBOH produces hallucinogen-like effects blockable by 5-HT2A antagonist M100907, but not 5-HT2C antagonist RS102221.
Brain-penetrant, highly potent and selective 5-HT2A receptor agonist with good in vitro & in vivo efficacy.
Timing deficits are observed in patients with schizophrenia. Serotonergic hallucinogens can also alter the subjective experience of time. Characterizing the mechanism through which the serotonergic system regulates timing will increase our understanding of the linkage between serotonin (5-HT) and schizophrenia
There is evidence that mGlu2/3 receptors regulate 5-HT2A signaling, interactions that have been theorized to play a role in the antipsychotic-like effects of mGlu2/3 agonists as well as the hallucinogenic effects of 5-HT2A agonists. One approach to unraveling this interaction
ACS chemical neuroscience, 5(3), 243-249 (2014-01-09)
N-Benzyl substitution of 5-HT2A receptor agonists of the phenethylamine structural class of psychedelics (such as 4-bromo-2,5-dimethoxyphenethylamine, often referred to as 2C-B) confer a significant increase in binding affinity as well as functional activity of the receptor. We have prepared a
The serotonin (5-HT) 2A receptor is the primary molecular target of serotonergic hallucinogens, which trigger large-scale perturbations of the cortex. Our understanding of how 5-HT2A activation may cause the effects of hallucinogens has been hampered by the receptor unselectivity of
5-Hydroxytryptamine 2A receptor (5-HT2AR) agonist psychedelics are increasingly recognized as potentially useful treatments of psychiatric disorders, such as obsessive-compulsive disorder, depression, anxiety, and drug dependence. There is limited understanding of the way they exert their therapeutic action, but inhibition of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.